Introduction & Contents

Introduction

It's time to take a look at the biopharmaceutical industry from outside the box. How will it change for the future?

The field of biotherapeutics is constantly growing and evolving, seeing advancements in technology and standardization, topped with shifting international focuses influenced by the recent COVID-19 pandemic.

Over the following pages, we’ll explore what could be in store for the industry over the next decade, including technologies, strategies and challenges yet to be overcome.

Jump to any article using the contents on the following page, or at any time using the Contents menu in the top left. There you can also download this eBook as a PDF.

1. Looking to 2030: Survey Report

We analyze the results of our recent survey looking at the changes the bioprocessing community and wider life sciences industries will see in the next decade.

2. From Big Data to Precise Understanding: The Quest for Meaningful Information

High-throughput technologies have transformed the biotechnology industry. The amount of data they generate is at least a hundred times higher now than it was two decades ago, primarily because of the rise of “-omic” technologies. As in many other industries, the biopharmaceutical sector entered the era of big data the day that high-throughput analytics were routinely implemented in experimental research.

3. A Look into How Academia and Biotech Can Work Better Together

Knud Jensen, PH.D, a professor in the Department of Chemistry at the University of Copenhagen discusses how academia and biotechs can mutually benefit by working closer together.

4. Future Trends in Proteins To Fight COVID-19

The global scientific community's attention has turned to COVID-19, a pandemic that has swept across the world. The future is now. The causative agent of COVID-19, the coronavirus SARS-CoV-2, has no vaccine, and no biologics or small molecules have yet been approved to treat it. There is a big opportunity for protein engineering to make an impact on this disease without a cure.

5. Can the Biotech Industry Lead Diversity in STEM?

As part of this year's Biotech Week Boston, stakeholders from across biopharma and biotech gathered for An Evening of Diversity and Inclusion. Industry thought leaders took part in a panel discussion centering on the importance of Diversity and Inclusion (D&I) initiatives in the biotech industry and addressing the challenges of changing perspectives.